person · Reporting owner

Lochner Daniel

Disclosed activity across 2 companies

Tapewire entity: 39073
SEC CIK: 0001791187

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Tectonic Therapeutic, Inc.TECX · Entity 5328	Chief Financial Officer	September 25, 2026	October 03, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Tectonic Therapeutic, Inc.

Report date September 25, 2026 · Filed October 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	58,024	Reported balance After 2026-09-25 transaction · row 1 1 source row Row 1 · 2026-09-25 · Tax withholding · Disposed 520 · Balance 58,024 F1: This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on September 25, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on September 25, 2025.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Oyster Point Pharma, Inc.

Report date January 29, 2022 · Filed January 04, 2023

Section 16 reporting ended · disclosed 2023-01-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	76,525	Reported balance After 2022-01-29 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2022-01-29 · Tax withholding · Disposed 938 · Balance 76,525 F1: The transaction reported represents the withholding of shares by the Issuer on January 29, 2022 to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units. This transaction is being reported late due to an inadvertent administrative error. F2: Includes an aggregate of 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Common StockSEC Table I · non-derivative	Direct	20,236	Reported balance After 2023-01-03 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2023-01-03 · Other · Disposed 56,289 · Balance 20,236 F3: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer was consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 4) F4: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent.
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2023-01-03 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2023-01-03 · Disposition to issuer · Disposed 20,236 · Balance 0 F5: This line item represents unvested restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested RSU or portion thereof was converted into a restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the total number of shares deliverable under such RSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such RSUs immediately prior to the Effective Time.
Performance Stock UnitsSEC Table II · derivative / convertible security · Expires 2032-07-05	Direct	0	Reported balance After 2023-01-03 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2023-01-03 · Disposition to issuer · Disposed 300,000 · Balance 0 F6: This line item represents performance stock units ("PSUs") held by the Reporting Person. Each PSU represents a contingent right to receive one share of common stock of the Issuer. F7: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested PSU was converted into a time-based vesting restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the target number of shares deliverable under such PSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such PSUs immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.51 · Expires 2029-07-25	Direct	0	Reported balance After 2023-01-03 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2023-01-03 · Disposition to issuer · Disposed 161,251 · Balance 0 F10: Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration. F8: This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings. F9: In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.65 · Expires 2030-02-03	Direct	0	Reported balance After 2023-01-03 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2023-01-03 · Disposition to issuer · Disposed 72,648 · Balance 0 F10: Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration. F8: This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings. F9: In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.77 · Expires 2031-01-29	Direct	0	Reported balance After 2023-01-03 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-01-03 · Disposition to issuer · Disposed 50,500 · Balance 0 F10: Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration. F8: This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings. F9: In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.78 · Expires 2031-08-26	Direct	0	Reported balance After 2023-01-03 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-01-03 · Disposition to issuer · Disposed 45,000 · Balance 0 F10: Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration. F8: This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings. F9: In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2032-01-09	Direct	0	Reported balance After 2023-01-03 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-01-03 · Disposition to issuer · Disposed 87,900 · Balance 0 F10: Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration. F8: This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings. F9: In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: The transaction reported represents the withholding of shares by the Issuer on January 29, 2022 to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units. This transaction is being reported late due to an inadvertent administrative error.

F2: Includes an aggregate of 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F3: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer was consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 4)

F4: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent.

F5: This line item represents unvested restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested RSU or portion thereof was converted into a restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the total number of shares deliverable under such RSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such RSUs immediately prior to the Effective Time.

F6: This line item represents performance stock units ("PSUs") held by the Reporting Person. Each PSU represents a contingent right to receive one share of common stock of the Issuer.

F7: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested PSU was converted into a time-based vesting restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the target number of shares deliverable under such PSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such PSUs immediately prior to the Effective Time.

F8: This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings.

F9: In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time.

F10: Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 25, 2026 Filed Oct 3, 2026 01:02 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	Tax withholdingCommon Stock	520	$23.67	$12,308.40	Disclosure SEC source: 0001791187-26-000010 · form4-10022026_091013.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,024 F1 · shares: This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on September 25, 2025. Read SEC document
September 03, 2026 Filed Sep 8, 2026 20:45 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	GrantEmployee Stock Option (Right to Buy) · Derivative	24,250	$0.00 Strike: $29.92	$0.00	Disclosure SEC source: 0001791187-26-000008 · form4-09082026_040905.xml · derivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,250 Underlying: Common Stock · 24,250 shares Expires 2036-09-02 F1 · derivative.exercise_date: 1/8th of the shares subject to the option vest on September 3, 2026 with the remaining shares subject to the option vesting in the following 42 equal monthly installments beginning on October 3, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document
June 11, 2026 Filed Jun 12, 2026 16:30 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	GrantPerformance Stock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $16.80	$0.00	Disclosure SEC source: 0001791187-26-000006 · form4-06122026_040619.xml · derivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2034-06-19 F1 · shares: Represents the number of shares earned under a performance-based stock option award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based conditions of the option award, the option was not reportable under Section 16 until the performance conditions were certified by the Issuer's Board of Directors, which occurred on June 11, 2026. The option reported on this form represents 50% of the total number of shares underlying the performance option subject to the option award. The remaining 50% of the shares will be earned upon the satisfaction of additional performance criteria. F2 · derivative.exercise_date: The shares underlying the option are fully vested and immediately exercisable as of June 1, 2026. Read SEC document
March 04, 2026 Filed Mar 5, 2026 17:43 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	GrantEmployee Stock Option (Right to Buy) · Derivative	24,250	$0.00 Strike: $27.41	$0.00	Disclosure SEC source: 0001791187-26-000005 · form4-03052026_100327.xml · derivative · entry 2 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,250 Underlying: Common Stock · 24,250 shares Expires 2036-03-03 F2 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on April 4, 2026, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document
March 04, 2026 Filed Mar 5, 2026 17:43 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	GrantCommon Stock	26,500	$0.00	$0.00	Disclosure SEC source: 0001791187-26-000005 · form4-03052026_100327.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,544 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of March 4, 2027, March 4, 2028 and March 4, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document
February 10, 2026 Filed Feb 11, 2026 17:32 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	6,000	$21.61	$129,660.00	Disclosure SEC source: 0001791187-26-000003 · form4-02112026_100208.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,044 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.24 to $21.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document
February 04, 2026 Filed Feb 10, 2026 16:04 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	Tax withholdingCommon Stock	2,077	$23.22	$48,227.94	Disclosure SEC source: 0001791187-26-000002 · form4-02102026_090247.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,044 F1 · shares: This transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of the restricted stock units granted on February 4, 2025. Read SEC document
September 25, 2025 Filed Sep 29, 2025 17:00 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	GrantEmployee Stock Option (Right to Buy) · Derivative	9,860	$0.00 Strike: $14.71	$0.00	Disclosure SEC source: 0001791187-25-000003 · form4-09292025_050905.xml · derivative · entry 2 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,860 Underlying: Common Stock · 9,860 shares Expires 2035-09-24 F3 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on October 25, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document
September 25, 2025 Filed Sep 29, 2025 17:00 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	GrantCommon Stock	5,430	$0.00	$0.00	Disclosure SEC source: 0001791187-25-000003 · form4-09292025_050905.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,121 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of September 25, 2026, September 25, 2027 and September 25, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date. F2 · balance_after: Please note that the total number of securities beneficially owned following the reported transaction has been corrected to reflect the correct amount. The amount reported on the Reporting Person's Form 4 filed with the Securities and Exchange Commission on February 7, 2025 should have reflected that the total number of securities beneficially owned following the reported transaction was 22,691 shares instead of 4,617 shares. Read SEC document
February 05, 2025 Filed Feb 7, 2025 16:19 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	PurchaseCommon Stock	4,617	$54.14	$249,964.38	Disclosure SEC source: 0001415889-25-003350 · form4-02072025_090225.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,617 F1 · kind: These shares of common stock were purchased in a private placement transaction on February 5, 2025, which was previously announced on the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2025. These shares were offered and sold in reliance on the exemption afforded by Regulation D of the Securities Act of 1933, as amended. F1 · shares: These shares of common stock were purchased in a private placement transaction on February 5, 2025, which was previously announced on the Issuer's Current Report on Form 8-K, filed with the Securities and Exchange Commission on February 3, 2025. These shares were offered and sold in reliance on the exemption afforded by Regulation D of the Securities Act of 1933, as amended. Read SEC document
February 04, 2025 Filed Feb 6, 2025 16:05 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	GrantEmployee Stock Option (Right to Buy) · Derivative	32,862	$0.00 Strike: $48.01	$0.00	Disclosure SEC source: 0001415889-25-003227 · form4-02062025_040206.xml · derivative · entry 2 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,862 Underlying: Common Stock · 32,862 shares Expires 2035-02-03 F2 · derivative.exercise_date: The shares subject to the option vest in 48 equal monthly installments beginning on March 4, 2025, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document
February 04, 2025 Filed Feb 6, 2025 16:05 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	GrantCommon Stock	18,074	$0.00	$0.00	Disclosure SEC source: 0001415889-25-003227 · form4-02062025_040206.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,074 F1 · shares: These shares are represented by restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The shares shall vest in 3 equal annual installments on each of February 4, 2026, February 4, 2027 and February 4, 2028, subject to the Reporting Person's continued service to the Issuer on each such vesting date. Read SEC document
June 20, 2024 Filed Jun 24, 2024 16:18 UTC	Tectonic Therapeutic, Inc. TECX · Entity 5328	GrantEmployee Stock Option (Right to Buy) · Derivative	118,000	$0.00 Strike: $16.80	$0.00	Disclosure SEC source: 0001415889-24-017958 · form4-06242024_080618.xml · derivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,000 Underlying: Common Stock · 118,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The shares subject to the option vest as to 25% of the shares on June 20, 2025 with the remainder vesting in the following 36 equal monthly installments, subject to the Reporting Person's continued service on each such vesting date and to certain change of control acceleration provisions. Read SEC document
January 03, 2023 Filed Jan 4, 2023 17:04 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Disposition to issuerStock Option (Right to Buy) · Derivative	87,900	Not disclosed Strike: $16.00	Not disclosed	Disclosure SEC source: 0001209191-23-001073 · doc4.xml · derivative · entry 9 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 87,900 shares Expires 2032-01-09 F10 · price: Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration. F8 · derivative.exercise_date: This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings. F9 · derivative.exercise_date: In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time. Read SEC document
January 03, 2023 Filed Jan 4, 2023 17:04 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Disposition to issuerStock Option (Right to Buy) · Derivative	45,000	Not disclosed Strike: $13.78	Not disclosed	Disclosure SEC source: 0001209191-23-001073 · doc4.xml · derivative · entry 8 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2031-08-26 F10 · price: Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration. F8 · derivative.exercise_date: This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings. F9 · derivative.exercise_date: In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time. Read SEC document
January 03, 2023 Filed Jan 4, 2023 17:04 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Disposition to issuerStock Option (Right to Buy) · Derivative	50,500	Not disclosed Strike: $18.77	Not disclosed	Disclosure SEC source: 0001209191-23-001073 · doc4.xml · derivative · entry 7 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,500 shares Expires 2031-01-29 F10 · price: Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration. F8 · derivative.exercise_date: This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings. F9 · derivative.exercise_date: In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time. Read SEC document
January 03, 2023 Filed Jan 4, 2023 17:04 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Disposition to issuerStock Option (Right to Buy) · Derivative	72,648	Not disclosed Strike: $32.65	Not disclosed	Disclosure SEC source: 0001209191-23-001073 · doc4.xml · derivative · entry 6 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,648 shares Expires 2030-02-03 F10 · price: Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration. F8 · derivative.exercise_date: This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings. F9 · derivative.exercise_date: In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time. Read SEC document
January 03, 2023 Filed Jan 4, 2023 17:04 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Disposition to issuerStock Option (Right to Buy) · Derivative	161,251	Not disclosed Strike: $11.51	Not disclosed	Disclosure SEC source: 0001209191-23-001073 · doc4.xml · derivative · entry 5 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 161,251 shares Expires 2029-07-25 F10 · price: Each vested and unvested stock option that has an exercise price per share that is equal to or greater than the Per Share Price will be canceled for no consideration. F8 · derivative.exercise_date: This line item represents stock options held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding vested stock option with an exercise price less than $13.00 was canceled and converted into the right to receive an amount in cash, equal to the excess, if any, of the Per Share Price over the exercise price applicable to such stock option, less applicable tax withholdings. F9 · derivative.exercise_date: In addition, pursuant to the Merger Agreement, at the Effective Time, each outstanding, unvested and unexercised stock option with an exercise price less than $13.00 will be converted into an option to purchase a number of shares of Viatris common stock (rounded down to the nearest whole share) determined by multiplying the number of shares deliverable under such stock option as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), and with an exercise price per share that is equal to the quotient (rounded up to the nearest cent) of the exercise price per share of such stock option as of immediately prior to the Effective Time divided by the Equity Award Exchange Ratio, subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such stock option immediately prior to the Effective Time. Read SEC document
January 03, 2023 Filed Jan 4, 2023 17:04 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Disposition to issuerPerformance Stock Units · Derivative	300,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-001073 · doc4.xml · derivative · entry 4 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300,000 shares Expires 2032-07-05 F6 · derivative.exercise_price: This line item represents performance stock units ("PSUs") held by the Reporting Person. Each PSU represents a contingent right to receive one share of common stock of the Issuer. F7 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested PSU was converted into a time-based vesting restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the target number of shares deliverable under such PSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such PSUs immediately prior to the Effective Time. F7 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested PSU was converted into a time-based vesting restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the target number of shares deliverable under such PSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such PSUs immediately prior to the Effective Time. Read SEC document
January 03, 2023 Filed Jan 4, 2023 17:04 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Disposition to issuerCommon Stock	20,236	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-001073 · doc4.xml · nonDerivative · entry 3 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · shares: This line item represents unvested restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested RSU or portion thereof was converted into a restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the total number of shares deliverable under such RSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such RSUs immediately prior to the Effective Time. F5 · price: This line item represents unvested restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the Merger Agreement, at the Effective Time, each outstanding and unvested RSU or portion thereof was converted into a restricted stock unit with respect to Viatris common stock (rounded down to the nearest whole share) determined by multiplying the total number of shares deliverable under such RSUs as of immediately prior to the Effective Time and the Equity Award Exchange Ratio (as defined in the Merger Agreement), subject to substantially the same terms and conditions, including vesting conditions, as were applicable to such RSUs immediately prior to the Effective Time. Read SEC document
January 03, 2023 Filed Jan 4, 2023 17:04 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	OtherCommon Stock	56,289	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-23-001073 · doc4.xml · nonDerivative · entry 2 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,236 F3 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 7, 2022, among the Issuer, Iris Purchaser Inc. ("Purchaser"), a wholly owned subsidiary of Viatris, Inc. ("Viatris"), and Viatris, Purchaser commenced a tender offer (the "Offer") to purchase all the outstanding common stock of the Issuer for the Per Share Price (as defined below). On January 3, 2023, the Offer was consummated, after which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). At the consummation of the Offer and the Merger, respectively, (i) Purchaser purchased all shares of Issuer's common stock that were validly tendered pursuant to the Offer for a cash payment equal to the Per Share Price and (ii) each share of the Issuer's common stock that was issued and outstanding immediately prior to the effective time of the Merger (the "Effective Time")(continued in Footnote 4) F4 · price: (other than shares that were held (a) by the Issuer (including any treasury shares) or by Viatris or Purchaser or any other direct or indirect wholly owned subsidiary of Viatris or (b) by stockholders of the Issuer who had properly exercised and perfected, and not withdrawn or otherwise lost, their appraisal rights under the Delaware General Corporate Law) was cancelled and converted into the right to receive (a) a cash payment of $11.00 per share (the "Cash Amount") and (b) one non-transferable contractual contingent value right representing the right to receive any applicable milestone payment if specified milestones are achieved (the "Milestone Payment" and together with the Cash Amount, the "Per Share Price") pursuant to a Contingent Value Rights Agreement, dated January 3, 2023, by and between Viatris and American Stock Transfer & Trust Company, LLC as Rights Agent. Read SEC document
December 01, 2022 Filed Dec 6, 2022 08:50 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Tax withholdingCommon Stock	3,258	$11.20	$36,489.60	Disclosure SEC source: 0001209191-22-059938 · doc4.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,463 F1 · kind: The transaction reported represents the withholding of shares by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units (the "RSUs"). Such RSUs were previously reported on the Reporting Person's Form 4 as to (i) 11,222 filed with the Securities and Exchange Commission on February 2, 2021 (the "2021 Award"); and (ii) 19,500 filed with the Securities and Exchange Commission on January 11, 2022 (the "2022 Award"). 2,805 RSUs of the 2021 Award and 4,875 RSUs of the 2022 Award were subsequently accelerated, effective December 1, 2022, resulting in the withholding being reported herein. Read SEC document
July 06, 2022 Filed Jul 8, 2022 16:55 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	GrantPerformance Stock Units · Derivative	300,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-041676 · doc4.xml · derivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-07-05 F1 · derivative.exercise_price: Represents a grant of performance stock units (the "PSUs"). Each PSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · derivative.exercise_date: The PSUs will vest as to (i) 50% on July 6, 2023; and (ii) 50% at such time, if any, beginning on July 6, 2023 and ending on July 6, 2024, the 30 day volume-weighted average stock price reaches $6.00 per share (the "VWAP Vesting Period"), subject to the Reporting Person's continuous service to the Issuer through each such date. For clarity, the applicable thirty (30) consecutive day period must occur entirely during the VWAP Vesting Period and the thirty (30) day volume-weighted average stock price will be measured during any thirty (30) consecutive trading days during such VWAP Vesting Period. Read SEC document
January 29, 2022 Filed Jan 4, 2023 17:04 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Tax withholdingCommon Stock	938	$11.70	$10,974.60	Disclosure SEC source: 0001209191-23-001073 · doc4.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,525 F1 · kind: The transaction reported represents the withholding of shares by the Issuer on January 29, 2022 to satisfy the Reporting Person's tax withholding obligations in connection with the non-reportable vesting and settlement of restricted stock units. This transaction is being reported late due to an inadvertent administrative error. F2 · balance_after: Includes an aggregate of 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document
January 09, 2022 Filed Jan 11, 2022 19:45 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	GrantEmployee Stock Option (Right to Buy) · Derivative	87,900	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0001209191-22-002978 · doc4.xml · derivative · entry 2 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,900 Underlying: Common Stock · 87,900 shares Expires 2032-01-08 F3 · derivative.exercise_date: Options granted on January 9, 2022 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. 25% of the options shall vest and become exercisable on January 7, 2023 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service to the Issuer through each such date. Read SEC document
January 09, 2022 Filed Jan 11, 2022 19:45 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	GrantCommon Stock	19,500	$0.00	$0.00	Disclosure SEC source: 0001209191-22-002978 · doc4.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,721 F1 · kind: Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · shares: 25% of the RSUs vest on January 7, 2023 and the remainder vest annually thereafter, in equal amounts, on the same day of the month as the grant date over the following 3 years, subject to the Reporting Person's continuous service to the Issuer through each such date. Read SEC document
November 01, 2021 Filed Nov 2, 2021 17:49 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	8,590	$0.00 Strike: $11.51	$0.00	Disclosure SEC source: 0001209191-21-062476 · doc4.xml · derivative · entry 2 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,251 Underlying: Common Stock · 8,590 shares Expires 2029-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the total number of shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances. Read SEC document
November 01, 2021 Filed Nov 2, 2021 17:49 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Exercise / conversionCommon Stock	8,590	$11.51	$98,870.90	Disclosure SEC source: 0001209191-21-062476 · doc4.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 02, 2021 Filed Sep 7, 2021 08:03 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $11.51	$0.00	Disclosure SEC source: 0001209191-21-054919 · doc4.xml · derivative · entry 2 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,841 Underlying: Common Stock · 7,500 shares Expires 2029-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the total number of shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances. Read SEC document
September 02, 2021 Filed Sep 7, 2021 08:03 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Exercise / conversionCommon Stock	7,500	$11.51	$86,325.00	Disclosure SEC source: 0001209191-21-054919 · doc4.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 26, 2021 Filed Aug 30, 2021 16:52 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	GrantEmployee Stock Option (Right to Buy) · Derivative	45,000	$0.00 Strike: $13.78	$0.00	Disclosure SEC source: 0001209191-21-053844 · doc4.xml · derivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2031-08-26 F1 · derivative.exercise_date: Options granted on August 26, 2021 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. One-fourth (1/4) of the options shall vest and become exercisable on August 26, 2022 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service to the Issuer through each such date. Read SEC document
July 28, 2021 Filed Jul 29, 2021 17:05 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $11.51	$0.00	Disclosure SEC source: 0001209191-21-048517 · doc4.xml · derivative · entry 2 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,341 Underlying: Common Stock · 7,500 shares Expires 2029-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the remaining shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances. Read SEC document
July 28, 2021 Filed Jul 29, 2021 17:05 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Exercise / conversionCommon Stock	7,500	$11.51	$86,325.00	Disclosure SEC source: 0001209191-21-048517 · doc4.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 24, 2021 Filed Feb 26, 2021 19:50 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	9,109	$0.00 Strike: $11.51	$0.00	Disclosure SEC source: 0001209191-21-015032 · doc4.xml · derivative · entry 2 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,841 Underlying: Common Stock · 9,109 shares Expires 2029-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the remaining shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances. Read SEC document
February 24, 2021 Filed Feb 26, 2021 19:50 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Exercise / conversionCommon Stock	9,109	$11.51	$104,844.59	Disclosure SEC source: 0001209191-21-015032 · doc4.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,631 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 29, 2021 Filed Feb 2, 2021 18:32 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	GrantEmployee Stock Option (Right to Buy) · Derivative	50,500	$0.00 Strike: $18.77	$0.00	Disclosure SEC source: 0001209191-21-006929 · doc4.xml · derivative · entry 2 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,500 Underlying: Common Stock · 50,500 shares Expires 2031-01-28 F3 · derivative.exercise_date: Options granted on January 29, 2021 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. 25% of the options shall vest and become exercisable on January 29, 2022 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service to the Issuer through each such date. Read SEC document
January 29, 2021 Filed Feb 2, 2021 18:32 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	GrantCommon Stock	11,222	$0.00	$0.00	Disclosure SEC source: 0001209191-21-006929 · doc4.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,522 F1 · kind: Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · shares: 25% of the RSUs vest on January 29, 2022 and the remainder vest annually thereafter on the same day of the month as the grant date over the following 3 years, subject to the Reporting Person's continuous service to the Issuer through each such date. Read SEC document
September 25, 2020 Filed Sep 28, 2020 18:12 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	4,000	$0.00 Strike: $11.51	$0.00	Disclosure SEC source: 0001209191-20-052252 · doc4.xml · derivative · entry 2 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,950 Underlying: Common Stock · 4,000 shares Expires 2029-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the remaining shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances. Read SEC document
September 25, 2020 Filed Sep 28, 2020 18:12 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Exercise / conversionCommon Stock	4,000	$11.51	$46,040.00	Disclosure SEC source: 0001209191-20-052252 · doc4.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 11, 2020 Filed Aug 12, 2020 20:32 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative	4,000	$0.00 Strike: $11.51	$0.00	Disclosure SEC source: 0001209191-20-046490 · doc4.xml · derivative · entry 2 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,950 Underlying: Common Stock · 4,000 shares Expires 2029-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The Option was granted on July 25, 2019 under the Oyster Point Pharma, Inc. 2016 Equity Incentive Plan. One quarter of the total number of shares subject to the option vested on July 22, 2020, and one forty-eighth of the remaining shares continue to vest monthly thereafter, subject to continued service to the Issuer through each such vesting date. The award is subject to vesting acceleration under certain circumstances. Read SEC document
August 11, 2020 Filed Aug 12, 2020 20:32 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	Exercise / conversionCommon Stock	4,000	$11.51	$46,040.00	Disclosure SEC source: 0001209191-20-046490 · doc4.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 11, 2020 Filed Aug 18, 2020 18:18 UTC Amendment	Oyster Point Pharma, Inc. OYST · Entity 15903	Exercise / conversionCommon Stock	4,000	$11.51	$46,040.00	Disclosure SEC source: 0001209191-20-047287 · doc4a.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 03, 2020 Filed Feb 5, 2020 16:10 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	GrantEmployee Stock Option (Right to Buy) · Derivative	72,648	$0.00 Strike: $32.65	$0.00	Disclosure SEC source: 0000899243-20-003254 · doc4.xml · derivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,648 Underlying: Common Stock, par value $0.001 per share · 72,648 shares Expires 2030-02-02 F1 · derivative.exercise_date: Option granted on February 3, 2019 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan (the "Plan"). One quarter of the total number of shares subject to the option shall vest one year after January 1, 2020, and one thirty-sixth of the remaining shares shall continue to vest, monthly thereafter, subject to continued service to the Issuer through each such vesting date. Read SEC document
November 04, 2019 Filed Nov 5, 2019 06:08 UTC	Oyster Point Pharma, Inc. OYST · Entity 15903	PurchaseCommon Stock, par value $0.001 per share	6,300	$16.00	$100,800.00	Disclosure SEC source: 0000899243-19-026636 · doc4.xml · nonDerivative · entry 1 Lochner Daniel · CIK 0001791187 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,300 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.